# Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS

> **NCT01757015** · PHASE3 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** NVA237
- **DRUG:** Placebo to NVA237

## Key facts

- **NCT ID:** NCT01757015
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-04
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01757015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01757015, "Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01757015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*